

# ACCORD 2 Newsletter

ACCORD – a national Phase 2, CMO prioritised study funded by UKRI and supported by the NIHR to develop the next generation of drugs for COVID-19.

The drugs currently in trial are:

- **Bemcentinib** – AXL inhibitor which may prevent viral infection and lung inflammation
- **MEDI3506** – an anti-IL-33 monoclonal antibody
- **Acalabrutinib** – a Bruton's tyrosine kinase (BTK) inhibitor
- **Zilucoplan** – a complement C5 inhibitor that could block severe inflammatory responses

## ACCORD Sites

SIV's and IP shipment are taking place this week on the Arm 003 - MEDI3506 sub protocol which will take us up to 18 sites on that arm alone!

## Recruitment Figures so far:

<b>Arm 002 Bemcentinib</b> -	<b>4</b>
<b>Arm 003 MEDI3506</b> -	<b>10</b>
<b>Arm 004 Acalabrutinib</b> -	<b>6</b>
<b>Arm 006 Zilucoplan</b> -	<b>5</b>



## Meet your CRA!



My name is Jennifer Allen and I am a Senior CRA for IQVIA and have been monitoring for 3.5 years.

I hold an MSc in Biomedical Science and a PhD in Clinical and Translational Medicine from UCD and am based in Dublin, Ireland.

I love health and fitness so am glad the gyms have finally opened! I also have two dogs, Kiko and Jess.

I am your point of contact on the Acalabrutinib arm and also support the MEDI-3506 arm.

## GOOD NEWS!!

Translated PIS/ICF's have started to arrive in the Sponsor office and just require a few editorial changes before being sent out to sites.

The first sets of languages available are Gujarati, Urdu and Punjabi and should be on their way to you soon via your CRA.

## Items to note:

Protocol clarification Memo - The memo clarifies the discrepancy between the Protocol Amendment Summary/Site Training and the actual protocol in regards to Exclusion Criteria 6: Anticipated transfer to another hospital that is not a study centre within 72 hours.

Zilucoplan 006 study only: Please ensure samples for Covance are sent to Covance directly.